Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist
Choose a source to read (4)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
1 additional source qualifications - review before use
Adults; named product and route only. Selected dosing and renal summary, not the full prescribing information.
Renal measure
No renal-function dose bands specified for this summary.
Source revision
DailyMed updated 2024-11-13.
Retrieved
2026-09-05 (not the revision date)
Dosing / renal protocol and limits
Adult hypertension or diabetic nephropathy: usual starting dose 50 mg orally once daily; increase to 100 mg daily according to blood pressure response. A 25-mg start is recommended with possible intravascular depletion. Renal impairment alone does not require adjustment unless volume depletion is also present. Monitor creatinine and potassium and reassess volume status. The fetal-toxicity warning remains applicable. This adult single-agent statement does not apply to pediatric low-GFR use or a losartan/hydrochlorothiazide combination.
Source revision: DailyMed updated 2024-11-13. | Retrieved: 2026-09-05. Retrieval date is not the revision date.
All sources, comparison tools and evidence navigation
Source-first renal review
Evidence sources and renal implications
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Renal Drug Handbook, 5th edition - Losartan potassium
Historical adult renal/RRT summary. U.S. product identity anchored to the separate locally included DailyMed label. This is not a current U.S. product label.
Renal method: Book table headed GFR (mL/min); its preface states renal adjustments generally derive from Cockcroft-Gault CrCl. Do not silently relabel as indexed eGFR. Retrieved: 2026-09-05
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Select two distinct source versions. The complete stored summaries will appear below.
Source-by-source comparison
These protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
Source scope / renal recommendation differences
Cozaar - product and source limitations
Monitor renal function in susceptible patients. Consider withholding therapy for a clinically significant decline.
How to use this: Apply only to the stated formulation, indication and renal population.
Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.
Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.
Renal Drug Handbook, 5th edition - Losartan potassium
Historical adult renal/RRT summary. U.S. product identity anchored to the separate locally included DailyMed label. This is not a current U.S. product label.
Method: Book table headed GFR (mL/min); its preface states renal adjustments generally derive from Cockcroft-Gault CrCl. Do not silently relabel as indexed eGFR.
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Adult Losartan potassium - single agent. Use only the product, route, indication and renal-replacement setting explicitly stated in the source protocol selected below. Sources are alternatives to compare, not ingredients of a blended regimen.
SCOPE-losartan · Source section: Editorial scope; each clinical recommendation is separately attributed belowRenal section finder
NIH/NLM DailyMed - U.S. product labeling · Adults; named product and route only. Selected dosing and renal summary, not the full prescribing information.
Renal method: No renal-function dose bands specified for this summary. Source date: DailyMed updated 2024-11-13. Retrieved: 2026-09-05
Locally included source-specific summary. Regimen differences are not automatically resolved.
Dosing / renal protocol and limits
Adult hypertension or diabetic nephropathy: usual starting dose 50 mg orally once daily; increase to 100 mg daily according to blood pressure response. A 25-mg start is recommended with possible intravascular depletion. Renal impairment alone does not require adjustment unless volume depletion is also present. Monitor creatinine and potassium and reassess volume status. The fetal-toxicity warning remains applicable. This adult single-agent statement does not apply to pediatric low-GFR use or a losartan/hydrochlorothiazide combination.
Renal method: Clinical renal category or population named in the cited section Source date: DailyMed SPL version 9, effective 2026-01-20; posted Jan 21, 2026 Retrieved: 2026-11-07
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Renal guidance: 2, volume depletion; 5 and 8, renal function
Renal impairment alone does not require dose reduction. With intravascular depletion, start the adult hypertension regimen at 25 mg daily. Monitor renal function in susceptible patients. Consider withholding therapy for a clinically significant decline.
RDM73-cozaar-official-1 · Source locator: Renal guidance: 2, volume depletion; 5 and 8, renal function
Renal method: Use the renal measure explicitly present in the RX passage. Source date: Mirror revision not established in the reviewed passage. Retrieved: 2026-11-07
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
UK Renal Pharmacy Group / CRC Press · Historical adult renal/RRT summary. U.S. product identity anchored to the separate locally included DailyMed label. This is not a current U.S. product label.
Renal method: Book table headed GFR (mL/min); its preface states renal adjustments generally derive from Cockcroft-Gault CrCl. Do not silently relabel as indexed eGFR. Source date: 5th edition; 2019 copyright; historical reference Retrieved: 2026-09-05
Historical handbook cross-check; not a current U.S. protocol
Historical renal / replacement-therapy guidance
At 20-50 mL/min, retain the usual indication dose. At 10-20 and <10, the book recommends an initial 25 mg dose and response-based titration. PD/HD/high-flux use the <10 band; continuous therapy uses 10-20; the drug is described as not dialyzed. This conservative low-function starting approach is distinct from the U.S. label, which ties lower starting doses especially to volume depletion. Monitor potassium and renal function.
HB30-losartan-1 · Source locator: Printed page 611: renal impairment, RRT and other information
Source-specific limits
Separate source recommendation, not proof of agreement or contemporary clinical validation. Dialysis predictions are retained with their original certainty.
Source identity and provenance
Retrieved
2026-09-05
Handbook page
5th edition, printed p. 611; uploaded PDF p. 630
Renal-function method
Book table headed GFR (mL/min); its preface states renal adjustments generally derive from Cockcroft-Gault CrCl. Do not silently relabel as indexed eGFR.
Additional summaries stored on this page: 2 official-label, 1 RX List, 0 professional, 1 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.
